ResultsIQ

ResultsIQ › Latest results › Laurus Labs Limited

Laurus Labs Limited Q1 FY27 results deck summary

NSE: LAURUSLABS · BSE: 540222

Results deck of 24 Jul 2026, summarised by AI from the filing.

1Q FY27 revenue ₹2,026 cr, up 29% Y/Y, with EBITDA ₹644 cr and margin 31.8%, up 7.0% pts.

Key takeaways

  1. Revenue 1Q FY27 revenue ₹2,026 cr, up 29% Y/Y, driven by CDMO growth and Affordable Medicines led by FDF.
  2. EBITDA 1Q FY27 EBITDA ₹644 cr with margin 31.8%, up 7.0% pts Y/Y on favorable product mix and operational leverage.
  3. CDMO growth CDMO revenue rose to ₹870 cr in 1Q FY27 from ₹522 cr in 1Q FY26, with small molecules at ₹835 cr.
  4. Growth driver CDMO growth from late-stage clinical projects and commercial API supplies; Affordable Medicines from order book and US launches.
  5. Risk Macro-economic conditions in key global markets and regulatory changes could cause actual results to differ.

Original filing on BSE

Laurus Labs Limited Q1 FY27 results

As filed: Revenue ₹2,026 cr (+29% year on year), EBITDA ₹638 cr (+67% year on year), PAT ₹362 cr (+124% year on year), EBITDA margin 31.5% (+710 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,812 cr (+5% year on year), EBITDA ₹512 cr (+22% year on year), PAT ₹282 cr (+21% year on year), EBITDA margin 28.3% (+391 bps). Score 33 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 391 bps year on year. Consolidated profit +21% but standalone -24%. Share price after the results: +23.1% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹1,778 cr (+26% year on year), EBITDA ₹480 cr (+68% year on year), PAT ₹252 cr (+171% year on year), EBITDA margin 27.0% (+679 bps). Score 81 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 679 bps year on year. Revenue rose ₹363 cr on a year ago, more than the ₹220 cr it added the year before. Share price after the results: +5.1% in 28 days (Nifty 500: +1.7%).
  • H1 FY26: Revenue ₹3,223 cr, EBITDA ₹786 cr, PAT ₹356 cr, EBITDA margin 24.4%. Not scored. No consolidated results for the same half-year last year to compare yet (consolidated revenue ₹3,223 cr). Scored once a year-earlier consolidated half-year exists. Share price after the results: +5.9% in 29 days (Nifty 500: +0.1%).
  • Q1 FY26: Revenue ₹1,570 cr (+31% year on year), EBITDA ₹383 cr (+125% year on year), PAT ₹162 cr (+300% year on year), EBITDA margin 24.4% (+1,000 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue fell 9% from last quarter. Share price after the results: +5.1% in 28 days (Nifty 500: −1.3%).
  • Q4 FY25: Revenue ₹1,720 cr (+19% year on year), EBITDA ₹419 cr (+74% year on year), PAT ₹233 cr (+211% year on year), EBITDA margin 24.4% (+762 bps). Score 89 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 762 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −8.8% in 29 days (Nifty 500: +2.4%).
  • Q3 FY25: Revenue ₹1,415 cr (+18% year on year), EBITDA ₹286 cr (+57% year on year), PAT ₹93.0 cr (+300% year on year), EBITDA margin 20.2% (+498 bps). Score 89 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 498 bps year on year.
  • Q2 FY25: Revenue ₹1,224 cr (0% year on year), EBITDA ₹179 cr (−4% year on year), PAT ₹20.0 cr (−46% year on year), EBITDA margin 14.6% (−65 bps). Score 22 of 100, Below trend. EBITDA margin fell 65 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Laurus Labs Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.